Literature DB >> 17056121

Shaping of monocyte and macrophage function by adenosine receptors.

György Haskó1, Pál Pacher, Edwin A Deitch, E Sylvester Vizi.   

Abstract

Adenosine is an endogenous purine nucleoside that, following its release into the extracellular space, binds to specific adenosine receptors expressed on the cell surface. Adenosine appears in the extracellular space under metabolically stressful conditions, which are associated with ischemia, inflammation, and cell damage. There are 4 types of adenosine receptors (A(1), A(2A), A(2B) and A(3)) and all adenosine receptors are members of the G protein-coupled family of receptors. Adenosine receptors are expressed on monocytes and macrophages and through these receptors adenosine modulates monocyte and macrophage function. Since monocytes and macrophages are activated by the same danger signals that cause accumulation of extracellular adenosine, adenosine receptors expressed on macrophages represent a sensor system that provide monocytes and macrophages with information about the stressful environment. Adenosine receptors, thus, allow monocytes and macrophages to fine-tune their responses to stressful stimuli. Here, we review the consequences of adenosine receptor activation on monocyte/macrophage function. We will detail the effect of stimulating the various adenosine receptor subtypes on macrophage differentiation/proliferation, phagocytosis, and tissue factor (TF) expression. We will also summarize our knowledge of how adenosine impacts the production of extracellular mediators secreted by monocytes and macrophages in response to toll-like receptor (TLR) ligands and other inflammatory stimuli. Specifically, we will delineate how adenosine affects the production of superoxide, nitric oxide (NO), tumor necrosis factor-alpha, interleukin (IL)-12, IL-10, and vascular endothelial growth factor (VEGF). A deeper insight into the regulation of monocyte and macrophage function by adenosine receptors should assist in developing new therapies for inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17056121      PMCID: PMC2228265          DOI: 10.1016/j.pharmthera.2006.08.003

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  126 in total

Review 1.  Pattern recognition receptors: doubling up for the innate immune response.

Authors:  Siamon Gordon
Journal:  Cell       Date:  2002-12-27       Impact factor: 41.582

2.  G(i)-protein-dependent inhibition of IL-12 production is mediated by activation of the phosphatidylinositol 3-kinase-protein 3 kinase B/Akt pathway and JNK.

Authors:  Andrea la Sala; Massimo Gadina; Brian L Kelsall
Journal:  J Immunol       Date:  2005-09-01       Impact factor: 5.422

Review 3.  Ecto-enzyme and signaling functions of lymphocyte CD73.

Authors:  R Resta; Y Yamashita; L F Thompson
Journal:  Immunol Rev       Date:  1998-02       Impact factor: 12.988

4.  Activation of the adenosine A3 receptor in RAW 264.7 cells inhibits lipopolysaccharide-stimulated tumor necrosis factor-alpha release by reducing calcium-dependent activation of nuclear factor-kappaB and extracellular signal-regulated kinase 1/2.

Authors:  Lynn Martin; Sandeep C Pingle; Daniel M Hallam; Leonard P Rybak; Vickram Ramkumar
Journal:  J Pharmacol Exp Ther       Date:  2005-09-27       Impact factor: 4.030

5.  A role for adenosine deaminase in human monocyte maturation.

Authors:  D Fischer; M B Van der Weyden; R Snyderman; W N Kelley
Journal:  J Clin Invest       Date:  1976-08       Impact factor: 14.808

6.  ATP suppression of interleukin-12 and tumour necrosis factor-alpha release from macrophages.

Authors:  G Haskó; D G Kuhel; A L Salzman; C Szabó
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

7.  Adenosine suppresses activation of nuclear factor-kappaB selectively induced by tumor necrosis factor in different cell types.

Authors:  Sekhar Majumdar; Bharat B Aggarwal
Journal:  Oncogene       Date:  2003-02-27       Impact factor: 9.867

8.  An angiogenic switch in macrophages involving synergy between Toll-like receptors 2, 4, 7, and 9 and adenosine A(2A) receptors.

Authors:  Grace Pinhal-Enfield; Madhuri Ramanathan; Gyorgy Hasko; Stefanie N Vogel; Andrew L Salzman; Geert-Jan Boons; S Joseph Leibovich
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

Review 9.  The coordination of signaling during Fc receptor-mediated phagocytosis.

Authors:  Joel A Swanson; Adam D Hoppe
Journal:  J Leukoc Biol       Date:  2004-10-05       Impact factor: 4.962

10.  Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes.

Authors:  M Kobayashi; L Fitz; M Ryan; R M Hewick; S C Clark; S Chan; R Loudon; F Sherman; B Perussia; G Trinchieri
Journal:  J Exp Med       Date:  1989-09-01       Impact factor: 14.307

View more
  85 in total

1.  Tissue-resident ecto-5' nucleotidase (CD73) regulates leukocyte trafficking in the ischemic brain.

Authors:  Danica Petrovic-Djergovic; Matthew C Hyman; Jessica J Ray; Diane Bouis; Scott H Visovatti; Takanori Hayasaki; David J Pinsky
Journal:  J Immunol       Date:  2012-01-30       Impact factor: 5.422

Review 2.  Adenosine receptors and asthma.

Authors:  R A Brown; D Spina; C P Page
Journal:  Br J Pharmacol       Date:  2008-03       Impact factor: 8.739

Review 3.  A(2B) adenosine receptors in immunity and inflammation.

Authors:  György Haskó; Balázs Csóka; Zoltán H Németh; E Sylvester Vizi; Pál Pacher
Journal:  Trends Immunol       Date:  2009-05-07       Impact factor: 16.687

4.  New bioinformatics approach to analyze gene expressions and signaling pathways reveals unique purine gene dysregulation profiles that distinguish between CD and UC.

Authors:  Leszek Rybaczyk; Andrew Rozmiarek; Kristin Circle; Iveta Grants; Bradley Needleman; Jacqueline E Wunderlich; Kun Huang; Fievos L Christofi
Journal:  Inflamm Bowel Dis       Date:  2009-07       Impact factor: 5.325

Review 5.  Current status and challenges of cytokine pharmacology.

Authors:  Z Zídek; P Anzenbacher; E Kmonícková
Journal:  Br J Pharmacol       Date:  2009-04-03       Impact factor: 8.739

6.  Activation of the macrophage A2b adenosine receptor regulates tumor necrosis factor-alpha levels following vascular injury.

Authors:  Hongjie Chen; Dan Yang; Shannon H Carroll; Holger K Eltzschig; Katya Ravid
Journal:  Exp Hematol       Date:  2009-05       Impact factor: 3.084

7.  Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function.

Authors:  Balázs Csóka; Leonóra Himer; Zsolt Selmeczy; E Sylvester Vizi; Pál Pacher; Catherine Ledent; Edwin A Deitch; Zoltán Spolarics; Zoltán H Németh; György Haskó
Journal:  FASEB J       Date:  2008-07-14       Impact factor: 5.191

8.  Stimulation of A2B adenosine receptors protects against trauma-hemorrhagic shock-induced lung injury.

Authors:  Balázs Koscsó; Alexey Trepakov; Balázs Csóka; Zoltán H Németh; Pál Pacher; Holger K Eltzschig; György Haskó
Journal:  Purinergic Signal       Date:  2013-04-13       Impact factor: 3.765

9.  Lung interstitial macrophages alter dendritic cell functions to prevent airway allergy in mice.

Authors:  Denis Bedoret; Hugues Wallemacq; Thomas Marichal; Christophe Desmet; Florence Quesada Calvo; Emmanuelle Henry; Rodrigue Closset; Benjamin Dewals; Caroline Thielen; Pascal Gustin; Laurence de Leval; Nico Van Rooijen; Alain Le Moine; Alain Vanderplasschen; Didier Cataldo; Pierre-Vincent Drion; Muriel Moser; Pierre Lekeux; Fabrice Bureau
Journal:  J Clin Invest       Date:  2009-11-09       Impact factor: 14.808

10.  The ecto-ATPDase CD39 is involved in the acquisition of the immunoregulatory phenotype by M-CSF-macrophages and ovarian cancer tumor-associated macrophages: Regulatory role of IL-27.

Authors:  Sènan M d'Almeida; Gilles Kauffenstein; Charlotte Roy; Laetitia Basset; Loukas Papargyris; Daniel Henrion; Véronique Catros; Norbert Ifrah; Philippe Descamps; Anne Croue; Pascale Jeannin; Marc Grégoire; Yves Delneste; Julie Tabiasco
Journal:  Oncoimmunology       Date:  2016-04-28       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.